Modulation effects of Etlingera elatior ethanol extract as anti-inflammatory on chronic kidney disease in mice with hypertension and diabetes.

Abstract

The incidence of diabetes increased significantly around the world in accordance with lifestyle and change in eating behaviour. Streptozotocin-Nicotinamide (STZ-NA) is capable of inducing Diabetes Mellitus type 2 in experimental animals for insulin resistance. In this research, we inspect the therapeutic potential of Etlingera elatior ethanol extract (EEEE) on diabetes associated with diabetic nephropathy and hypertension complications in mice models. Diabetes and hypertension are induced in mice using STZ 45 mg/kgBB and NA 110 mg/kgBB, followed by unilateral ureter ligation (UUO) for 4 weeks after a week of STZ-NA induction. The EEEE solution was given in the last 4 weeks with doses of 200, 400, 600, and 800 mg/kgBB. The results of this study prove the effect of vanillic acid on improving systolic blood pressure, plasma creatinine, plasma glucose, albuminuria and reducing the inflammatory marker high sensitivity C-reactive protein (hs-CRP). Histopathology of kidney is under investigation for being part of diabetes hypertension pathology. Treatment using EEEE 600 and 800 mg/kgBB for 4 weeks in experimental mice results in the decrease of plasma glucose, systolic blood pressure, plasma creatinine, albuminuria, and hs-CRP, including the restoration of kidney histology significantly compared to 200 and 400 mg/kgBB doses. This result concludes that EEEE offers modulation effects on diabetes hypertension control by reducing blood glucose rate, blood pressure rate, kidney defect, and inflammation markers.